Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) from the KarMMa Study

Authors :: Nikhil C. Munshi
Jesús San-Miguel
Larry D. Anderson Jr.
Sagar Lonial
Anna Truppel-Hartmann
Jill Sanford
Everton Rowe
Timothy B. Campbell
Paula Rodriguez-Otero
Source :: Transplantation and Cellular Therapy. 28:S171
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Subjects :: Transplantation
Molecular Medicine
Immunology and Allergy
Cell Biology
Hematology

Full Text Access

Tools